ERBB2 and PTPN2 gene copy numbers as prognostic factors in HER2-positive metastatic breast cancer treated with trastuzumab

Trastuzumab has markedly improved the treatment and long-term prognosis of patients with HER2-positive breast cancer. A frequent clinical challenge in patients with relapsing and/or metastatic disease is de novo or acquired trastuzumab resistance, and to date no predictive biomarkers for palliative...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Oncol Lett
Main Authors: Ellegård, Sander, Veenstra, Cynthia, Pérez-Tenorio, Gizeh, Fagerström, Victor, Gårsjö, Jon, Gert, Krista, Sundquist, Marie, Malmström, Annika, Wingren, Sten, Elander, Nils O., Hallbeck, Anna-Lotta, Stål, Olle
Format: Artigo
Jezik:Inglês
Izdano: D.A. Spandidos 2019
Teme:
Articles
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6396168/
https://ncbi.nlm.nih.gov/pubmed/30867772
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2019.9998
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki